managing-congenital-heart-disease-adults

name	managing-congenital-heart-disease-adults
description	Structures ACHD evaluation with lesion-specific monitoring and pregnancy risk assessment. Use when managing adult congenital heart disease, evaluating ACHD patients, or assessing pregnancy risk in CHD.
tags	["management","cardiology","risk","patient-care"]
metadata	{"author":"casemark","practice_areas":["Cardiology","Interventional Cardiology","Electrophysiology"],"document_types":["Management Report"],"skill_modes":["Management","Coordination"]}

Managing Congenital Heart Disease Adults

Structures ACHD evaluation with lesion-specific monitoring and pregnancy risk assessment.

Why This Skill Exists

Over 1.5 million adults in the United States are living with congenital heart disease (CHD), and this population is growing as surgical advances have increased survival from childhood CHD to over 90%. However, these patients face lifelong cardiovascular complications including arrhythmias, heart failure, pulmonary hypertension, endocarditis, and the unique challenges of pregnancy with structural heart disease. The 2018 ACC/AHA Guideline for the Management of Adults with Congenital Heart Disease and the 2020 ESC Guidelines on ACHD provide comprehensive lesion-specific management recommendations.

ACHD patients frequently fall through gaps in the healthcare system — transitioning from pediatric to adult cardiology care results in lost follow-up for up to 60% of patients. General cardiologists may be unfamiliar with the hemodynamics of surgically corrected lesions. This skill ensures systematic ACHD evaluation aligned with guideline-based, lesion-specific protocols.

---

Checkpoint A: Pre-Draft Intake (Mandatory)

1. What is the specific congenital heart defect? (default: "Lesion not specified")
2. Has the defect been repaired surgically or percutaneously? What type of repair and when? (default: "Repair status unknown")
3. What is the current functional status (NYHA class)? (default: "Functional class not assessed")
4. What is the current anatomy — chamber sizes, LVEF, RVEF, valve function, residual shunts? (default: "Current imaging not provided")
5. Are there arrhythmias documented or suspected? (default: "Arrhythmia status unknown")
6. Is the patient female of childbearing potential? Is pregnancy planned? (default: "Pregnancy status not assessed")
7. Has the patient been seen at an ACHD-accredited center? (default: "ACHD center involvement not documented")
8. What is the current medication list and endocarditis prophylaxis status? (default: "Medications not reviewed")

Documents to Request

• Complete surgical/interventional history with operative reports
• Most recent echocardiogram (TTE ± TEE)
• Cardiac MRI (gold standard for RV assessment, Qp:Qs, conduit evaluation)
• Recent ECG and ambulatory monitoring
• Exercise stress test with functional capacity (METs, VO₂ max)
• Cardiac catheterization data (if hemodynamic assessment needed)
• CT chest/cardiac CT (for anatomy, coronary assessment, reintervention planning)
• Current medication list
• Labs: BNP/NT-proBNP, CBC, BMP, iron studies, SpO₂
• Genetic testing results if syndromic (Down, Turner, DiGeorge, Williams)

---

Step 1: ACHD Anatomic and Physiologic Classification

ACC/AHA ACHD Anatomic Complexity:

Complexity	Examples
Simple	Isolated small ASD, small VSD, mild pulmonic stenosis, repaired PDA, bicuspid aortic valve without dysfunction
Moderate	Repaired tetralogy of Fallot, AV canal defect, coarctation, Ebstein anomaly, moderate valve disease
Complex	Single ventricle (Fontan), transposition (post-Mustard/Senning or arterial switch), truncus arteriosus, Eisenmenger syndrome

ACHD Physiologic Stage (AP Classification):

Stage	Definition
A	No hemodynamic or anatomic sequelae; no arrhythmia; normal exercise capacity
B	Significant hemodynamic sequelae: volume/pressure overload, mild-moderate shunt, mild ventricular dysfunction, mild valve disease
C	Significant hemodynamic sequelae with symptoms: exercise limitation (NYHA II), progressive ventricular dilation/dysfunction
D	Severe sequelae: severe ventricular dysfunction, severe valve disease, Eisenmenger physiology, refractory arrhythmia, NYHA III–IV

---

Step 2: Lesion-Specific Management

Tetralogy of Fallot (Repaired):

• Residual issues: pulmonary regurgitation (PR), RV dilation, RVOT obstruction, VSD patch leak, arrhythmia
• Pulmonary valve replacement indication: severe PR with symptoms OR progressive RV dilation (RVEDVI > 150 mL/m²) or dysfunction (RVEF < 45%)
• Arrhythmia risk: VT (scar-related), sudden cardiac death risk stratified by QRS > 180 ms, non-sustained VT, severe RV dysfunction
• Monitoring: annual CMR, ECG, exercise test; Holter if arrhythmia symptoms

Transposition of the Great Arteries:

• Post-atrial switch (Mustard/Senning): systemic RV (failing long-term), baffle leaks/obstruction, sinus node dysfunction, atrial arrhythmias
• Post-arterial switch (Jatene): coronary ostial stenosis, neo-aortic root dilation, neo-aortic regurgitation, branch PA stenosis
• Congenitally corrected TGA (L-TGA): systemic RV failure, complete heart block (2% per year)

Fontan (Single Ventricle):

• Long-term complications: protein-losing enteropathy, plastic bronchitis, liver fibrosis/cirrhosis (Fontan-associated liver disease), atrial arrhythmias, thromboembolism
• Monitoring: annual echo, liver elastography, hepatic MRI every 2–3 years, AFP for HCC screening
• Anticoagulation: warfarin or DOAC (practice varies; warfarin preferred for fenestrated Fontan)
• Failing Fontan: consider Fontan revision or cardiac transplant evaluation

Eisenmenger Syndrome:

• Irreversible pulmonary vascular disease with right-to-left shunting
• Do NOT close the defect (shunt serves as pressure relief valve)
• Medical management: PAH-targeted therapy (ERA, PDE5i) — improves exercise capacity and symptoms
• Avoid: systemic vasodilators (worsen R→L shunt), dehydration, pregnancy (30–50% maternal mortality), general anesthesia (extreme caution)
• Phlebotomy only if symptomatic hyperviscosity AND Hct > 65% (not routine)

Coarctation of the Aorta (Repaired):

• Long-term: re-coarctation, hypertension (even after successful repair), bicuspid aortic valve disease, ascending aortic aneurysm, berry aneurysms
• Monitor: BP in all four extremities, annual imaging of aorta, BAV surveillance

---

Step 3: Arrhythmia Management in ACHD

Common Arrhythmias by Lesion:

Lesion	Common Arrhythmia
Repaired TOF	VT (RVOT scar-related), atrial flutter/fibrillation
Atrial switch (Mustard/Senning)	Sinus node dysfunction, intra-atrial reentrant tachycardia (IART)
Fontan	IART, atrial fibrillation/flutter
Ebstein anomaly	WPW (accessory pathways), SVT, AF
ASD (unrepaired)	AF/flutter (especially if repaired after age 40)

Principles:

• Catheter ablation is first-line for symptomatic SVT/IART when anatomy permits
• Antiarrhythmic drugs: amiodarone most effective but toxicity limits use; sotalol, flecainide (only if no structural dysfunction)
• ICD: for documented sustained VT/VF, or high-risk features in repaired TOF (QRS > 180 ms, severe RV dysfunction, NSVT, inducible VT on EP study)
• Pacemaker: sinus node dysfunction (post-atrial switch), progressive AV block (L-TGA: 2% per year)

---

Step 4: Pregnancy Risk Assessment

Modified WHO Classification for Pregnancy Risk in CHD:

mWHO Class	Risk	Examples	Recommendation
I	No increased risk	Small ASD, repaired simple lesions, isolated PVCs	Standard obstetric care
II	Mild increased risk	Unrepaired ASD/VSD, repaired TOF (good function), mild aortic stenosis	Tertiary center; cardiology follow-up
II–III	Moderate increased risk	Moderate LV dysfunction, Marfan with aorta < 40 mm, mechanical valve on anticoagulation	Specialist center; monthly-to-bimonthly cardiology
III	Significantly increased risk	Moderate-severe systemic ventricular dysfunction, Fontan with good function, moderate aortic dilation	Expert center; biweekly cardiology
IV	Pregnancy contraindicated	Eisenmenger syndrome, severe systemic ventricular dysfunction, severe aortic stenosis, Marfan with aorta > 45 mm, severe coarctation	Pregnancy should be avoided; contraception counseling mandatory

CARPREG II Risk Score:

• Variables: prior cardiac event, NYHA III/IV or cyanosis, mechanical valve, ventricular dysfunction, high-risk valve disease, coronary artery disease, high-risk aortopathy, no prior cardiac intervention, late pregnancy assessment
• Predicts adverse maternal cardiac events during pregnancy

Anticoagulation in Pregnancy:

• Warfarin: teratogenic (first trimester); lowest-risk strategy for mechanical valves may involve LMWH first trimester → warfarin second/third trimester → LMWH near delivery
• Heparin/LMWH: does not cross placenta; used when warfarin is contraindicated
• DOACs: contraindicated in pregnancy

---

Step 5: Ongoing Surveillance and Transition of Care

Follow-Up Intervals by Complexity:

Complexity	Follow-Up Interval	Location
Simple (AP Stage A)	Every 3–5 years	General cardiologist with ACHD knowledge
Moderate (AP Stage B)	Every 1–2 years	ACHD center
Complex (AP Stage C–D)	Every 6–12 months	ACHD-accredited center

Core Surveillance Components:

• Echocardiogram (annual for moderate/complex)
• Cardiac MRI (every 2–3 years for RV assessment, conduit evaluation, Fontan)
• ECG and Holter monitoring (annual or with symptoms)
• Exercise stress test with VO₂ max (every 1–2 years; peak VO₂ is a strong prognostic marker)
• BNP/NT-proBNP trending
• Liver assessment for Fontan patients (elastography, AFP)
• Dental health and endocarditis prophylaxis review

Transition of Care:

• Formal transition program from pediatric to adult cardiology at age 16–18
• Transfer to ACHD-accredited center by age 18–21
• Ensure comprehensive medical records transfer (surgical reports are critical)
• Address psychosocial needs: insurance, education, employment, contraception counseling

---

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is the specific congenital lesion identified with repair status documented?
2. Is the anatomic complexity and physiologic stage (AP classification) assigned?
3. Are lesion-specific complications and monitoring addressed?
4. Is pregnancy risk assessed using mWHO classification (if applicable)?
5. Is the follow-up plan assigned to the appropriate level of care (general vs. ACHD center)?

---

Quality Audit

• Congenital heart defect specifically identified
• Surgical/interventional history documented with dates and techniques
• ACC/AHA anatomic complexity classification assigned (simple/moderate/complex)
• AP physiologic stage documented (A–D)
• Current cardiac anatomy described (echo/CMR findings)
• RV function quantified (especially post-TOF, atrial switch, Fontan)
• Arrhythmia risk assessed for specific lesion
• Endocarditis prophylaxis indication reviewed
• Exercise capacity documented (METs or VO₂ max)
• Pregnancy risk classified by mWHO (if applicable)
• Contraception counseling documented for mWHO III–IV
• Follow-up interval and care location appropriate for complexity
• ACHD center referral made or documented if moderate/complex
• Psychosocial and transition of care needs addressed

---

Guidelines

1. All patients with moderate or complex ACHD should be followed at an ACHD-accredited center — general cardiologists may miss lesion-specific complications.
2. Cardiac MRI is the gold standard for RV assessment in repaired TOF and systemic RV patients — echocardiography alone is insufficient for these lesions.
3. Eisenmenger syndrome is an absolute contraindication to pregnancy (30–50% maternal mortality) and to defect closure — both are lethal interventions in this population.
4. Fontan patients require lifelong surveillance for liver disease — Fontan-associated liver disease (FALD) progresses silently and can develop hepatocellular carcinoma.
5. Exercise testing with VO₂ max is the single best prognostic tool in ACHD — declining peak VO₂ predicts hospitalization and mortality.
6. Endocarditis prophylaxis is indicated for: unrepaired cyanotic CHD, repaired CHD with residual defects at or adjacent to prosthetic material, and all prosthetic valves — for dental procedures involving gingival tissue or periapical region.
7. Anticoagulation in pregnant patients with mechanical valves requires a detailed risk-benefit discussion — warfarin provides best valve protection but is teratogenic in the first trimester.
8. QRS duration > 180 ms in repaired TOF is a validated marker for sudden cardiac death risk and should trigger evaluation for ICD or catheter ablation.